Drug Profile
Niclosamide capsules - ANA Therapeutics
Alternative Names: ANA-001Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator ANA Therapeutics
- Developer ANA Therapeutics; NeuroBo Pharmaceuticals
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 28 Mar 2024 NeuroBO Pharmaceuticals has patents pending for Niclosamide capsules in USA, Argentina and Europe
- 30 Mar 2023 Niclosamide capsules - ANA Therapeutics is available for licensing as of 04 Apr 2023. http://www.neurobopharma.com
- 04 Nov 2022 Phase-I clinical trials in COVID-2019 infections (Combination therapy) (PO) before November 2022